Literature DB >> 28219749

Behavioral phenotypes associated with MPTP induction of partial lesions in common marmosets (Callithrix jacchus).

Kimberley A Phillips1, Corinna N Ross2, Jennifer Spross3, Catherine J Cheng4, Alyssa Izquierdo5, K C Biju6, Cang Chen7, Senlin Li7, Suzette D Tardif8.   

Abstract

Parkinson's disease is a chronic neurodegenerative disorder with the core motor features of resting tremor, bradykinesia, rigidity, and postural instability. Non-motor symptoms also occur, and include cognitive dysfunction, mood disorders, anosmia (loss of smell), and REM sleep disturbances. As the development of medications and other therapies for treatment of non-motor symptoms is ongoing, it is essential to have animal models that aid in understanding the neural changes underlying non-motor PD symptoms and serve as a testing ground for potential therapeutics. We investigated several non-motor symptoms in 10 adult male marmosets using the MPTP model, with both the full (n=5) and partial (n=5) MPTP dosing regimens. Baseline data in numerous domains were collected prior to dosing; assessments in these same domains occurred post-dosing for 12 weeks. Marmosets given the partial MPTP dose (designed to mimic the early stages of the disease) differed significantly from marmosets given the full MPTP dose in several ways, including behavior, olfactory discrimination, cognitive performance, and social responses. Importantly, while spontaneous recovery of PD motor symptoms has been previously reported in studies of MPTP monkeys and cats, we did not observe recovery of any non-motor symptoms. This suggests that the neurochemical mechanisms behind the non-motor symptoms of PD, which appear years before the onset of symptoms, are independent of the striatal dopaminergic transmission. We demonstrate the value of assessing a broad range of behavioral change to detect non-motor impairment, anosmia, and differences in socially appropriate responses, in the marmoset MPTP model of early PD.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  MPTP; Non-motor symptoms; Nonhuman primate model; Parkinson’s disease

Mesh:

Year:  2017        PMID: 28219749      PMCID: PMC5410665          DOI: 10.1016/j.bbr.2017.02.010

Source DB:  PubMed          Journal:  Behav Brain Res        ISSN: 0166-4328            Impact factor:   3.332


  31 in total

1.  Mild cognitive impairment is common in Parkinson's disease patients with normal Mini-Mental State Examination (MMSE) scores.

Authors:  Eugenia Mamikonyan; Paul J Moberg; Andrew Siderowf; John E Duda; Tom Ten Have; Howard I Hurtig; Matthew B Stern; Daniel Weintraub
Journal:  Parkinsonism Relat Disord       Date:  2008-07-02       Impact factor: 4.891

2.  REM sleep behavior disorder in the marmoset MPTP model of early Parkinson disease.

Authors:  Peternella S Verhave; Marjan J Jongsma; Roland M Van den Berg; José C Vis; Raymond A P Vanwersch; August B Smit; Eus J W Van Someren; Ingrid H C H M Philippens
Journal:  Sleep       Date:  2011-08-01       Impact factor: 5.849

3.  Increased caudate dopamine turnover may contribute to the recovery of motor function in marmosets treated with the dopaminergic neurotoxin MPTP.

Authors:  S Rose; M Nomoto; E Kelly; G Kilpatrick; P Jenner; C D Marsden
Journal:  Neurosci Lett       Date:  1989-07-03       Impact factor: 3.046

4.  Behavioral motor recovery in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned squirrel monkey (Saimiri sciureus): changes in striatal dopamine and expression of tyrosine hydroxylase and dopamine transporter proteins.

Authors:  Giselle M Petzinger; Beth Fisher; Elizabeth Hogg; Avery Abernathy; Pablo Arevalo; Kerry Nixon; Michael W Jakowec
Journal:  J Neurosci Res       Date:  2006-02-01       Impact factor: 4.164

5.  What contributes to quality of life in patients with Parkinson's disease?

Authors:  A Schrag; M Jahanshahi; N Quinn
Journal:  J Neurol Neurosurg Psychiatry       Date:  2000-09       Impact factor: 10.154

6.  Neuropsychiatric behaviors in the MPTP marmoset model of Parkinson's disease.

Authors:  Susan H Fox; Naomi Visanji; Gaby Reyes; Philippe Huot; Jordi Gomez-Ramirez; Tom Johnston; Jonathan M Brotchie
Journal:  Can J Neurol Sci       Date:  2010-01       Impact factor: 2.104

7.  Behavioural effects of subthalamic nucleus lesions in the hemiparkinsonian marmoset (Callithrix jacchus).

Authors:  J M Henderson; L E Annett; E M Torres; S B Dunnett
Journal:  Eur J Neurosci       Date:  1998-02       Impact factor: 3.386

Review 8.  Assessment of cognitive and motor deficits in a marmoset model of stroke.

Authors:  Jonathan W B Marshall; Rosalind M Ridley
Journal:  ILAR J       Date:  2003

9.  No Lewy pathology in monkeys with over 10 years of severe MPTP Parkinsonism.

Authors:  Glenda Halliday; Maria Trinidad Herrero; Karen Murphy; Heather McCann; Francisco Ros-Bernal; Carlos Barcia; Hideo Mori; Francisco J Blesa; José A Obeso
Journal:  Mov Disord       Date:  2009-07-30       Impact factor: 10.338

Review 10.  Parkinson's disease: animal models and dopaminergic cell vulnerability.

Authors:  Javier Blesa; Serge Przedborski
Journal:  Front Neuroanat       Date:  2014-12-15       Impact factor: 3.856

View more
  10 in total

1.  Microglia, inflammation and gut microbiota responses in a progressive monkey model of Parkinson's disease: A case series.

Authors:  Valerie Joers; Gunasingh Masilamoni; Doty Kempf; Alison R Weiss; Travis M Rotterman; Benjamin Murray; Gul Yalcin-Cakmakli; Ronald J Voll; Mark M Goodman; Leonard Howell; Jocelyne Bachevalier; Stefan J Green; Ankur Naqib; Maliha Shaikh; Phillip A Engen; Ali Keshavarzian; Christopher J Barnum; Jonathon A Nye; Yoland Smith; Malú G Tansey
Journal:  Neurobiol Dis       Date:  2020-07-24       Impact factor: 5.996

Review 2.  The use of nonhuman primate models to understand processes in Parkinson's disease.

Authors:  Javier Blesa; Inés Trigo-Damas; Natalia López-González Del Rey; José A Obeso
Journal:  J Neural Transm (Vienna)       Date:  2017-03-29       Impact factor: 3.575

3.  Sex differences in cognitive aging: a 4-year longitudinal study in marmosets.

Authors:  Emily S Rothwell; Kathryn P Workman; Dongwei Wang; Agnès Lacreuse
Journal:  Neurobiol Aging       Date:  2021-09-20       Impact factor: 4.673

4.  Potential trade-off between olfactory and visual discrimination learning in common marmosets (Callithrix jacchus): Implications for the assessment of age-related cognitive decline.

Authors:  Elena M Golub; Bryce Conner; Mélise Edwards; Lacey Gillis; Agnès Lacreuse
Journal:  Am J Primatol       Date:  2022-08-08       Impact factor: 3.014

5.  One-year change in cognitive flexibility and fine motor function in middle-aged male and female marmosets (Callithrix jacchus).

Authors:  Kathryn P Workman; Brianna Healey; Alyssa Carlotto; Agnès Lacreuse
Journal:  Am J Primatol       Date:  2018-10-03       Impact factor: 2.371

6.  Sex Differences in Cognitive Flexibility and Resting Brain Networks in Middle-Aged Marmosets.

Authors:  M LaClair; M Febo; B Nephew; N J Gervais; G Poirier; K Workman; S Chumachenko; L Payne; M C Moore; J A King; A Lacreuse
Journal:  eNeuro       Date:  2019-07-25

7.  Motility Profile of Captive-Bred Marmosets Revealed by a Long-Term In-Cage Monitoring System.

Authors:  Masashi Koizumi; Naotake Nogami; Kensuke Owari; Akiyo Kawanobe; Terumi Nakatani; Kazuhiko Seki
Journal:  Front Syst Neurosci       Date:  2021-04-15

Review 8.  Experimental Models of Cognitive Impairment for Use in Parkinson's Disease Research: The Distance Between Reality and Ideal.

Authors:  Yaohua Fan; Jiajun Han; Lijun Zhao; Chunxiao Wu; Peipei Wu; Zifeng Huang; Xiaoqian Hao; YiChun Ji; Dongfeng Chen; Meiling Zhu
Journal:  Front Aging Neurosci       Date:  2021-11-29       Impact factor: 5.750

9.  Measurement of baseline locomotion and other behavioral traits in a common marmoset model of Parkinson's disease established by a single administration regimen of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: providing reference data for efficacious preclinical evaluations.

Authors:  Kiyoshi Ando; Takashi Inoue; Keigo Hikishima; Yuji Komaki; Kenji Kawai; Ryo Inoue; Chiyoko Nishime; Eiko Nishinaka; Koji Urano; Hideyuki Okano
Journal:  Behav Pharmacol       Date:  2020-02       Impact factor: 2.277

Review 10.  Animal models of Parkinson's disease: a guide to selecting the optimal model for your research.

Authors:  Joana Lama; Yazead Buhidma; Edward J R Fletcher; Susan Duty
Journal:  Neuronal Signal       Date:  2021-12-08
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.